Cargando…

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges

Melanoma and nonmelanoma skin cancers (NMSCs) are recognized as among the most common neoplasms, mostly in white people, with an increasing incidence rate. Among the NMSCs, squamous cell carcinoma (SCC) is the most prevalent malignancy known to affect people with a fair complexion who are exposed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ansary, Tuba M., Hossain, MD Razib, Komine, Mayumi, Ohtsuki, Mamitaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368833/ https://www.ncbi.nlm.nih.gov/pubmed/35955666 http://dx.doi.org/10.3390/ijms23158530

Ejemplares similares

Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation
por: Hossain, Md Razib, et al.
Publicado: (2021)

Inflammatory Molecules Associated with Ultraviolet Radiation-Mediated Skin Aging
por: Ansary, Tuba M., et al.
Publicado: (2021)

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?
por: Komine, Mayumi, et al.
Publicado: (2022)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022)

STAT3 Activation in Psoriasis and Cancers
por: Kishimoto, Megumi, et al.
Publicado: (2021)

Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis
por: Pittayapruek, Pavida, et al.
Publicado: (2016)

Risk Factors for the Development of Psoriasis
por: Kamiya, Koji, et al.
Publicado: (2019)

Diagnostic Clues for Pagetoid Bowen's Disease
por: Chiang, Binluen, et al.
Publicado: (2020)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes
por: Yano, Chizuko, et al.
Publicado: (2015)

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
por: Kishimoto, Megumi, et al.
Publicado: (2023)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
por: Boutros, Andrea, et al.
Publicado: (2021)

Acute generalized pustular bacterid
por: Kamiya, Koji, et al.
Publicado: (2017)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
por: Almangush, Alhadi, et al.
Publicado: (2021)

Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma
por: Aboul-Fettouh, Nader, et al.
Publicado: (2021)

Reactive nonsexually related acute genital ulcers
por: Ueda, Yoshitaka, et al.
Publicado: (2017)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy
por: Stinchcombe, Thomas E.
Publicado: (2014)

Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit
por: Yang, Yi, et al.
Publicado: (2022)

Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges
por: Lorini, Luigi, et al.
Publicado: (2023)

Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus
por: Heise, Joachim W, et al.
Publicado: (2001)

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
por: Okubo, Yukari, et al.
Publicado: (2021)

Predictors of immunotherapy benefit in Merkel cell carcinoma
por: Kacew, Alec J., et al.
Publicado: (2020)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
por: Ishitsuka, Yosuke, et al.
Publicado: (2021)

An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma
por: Huang, Yaxuan, et al.
Publicado: (2022)

Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
por: Zhu, Chao, et al.
Publicado: (2021)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors
por: Tago, Kenji, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_24btisbrs941r2oahhbpifprpt